Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Sarcoma 14Ovarian Neoplasms 6Neoplasms 5Liposarcoma 5Leiomyosarcoma 5Liposarcoma, Myxoid 3Breast Neoplasms 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Osteosarcoma 2Neoplasms by Site 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Ichthyosis, X-Linked 2Endometrial Neoplasms 2Uterine Neoplasms 1Solitary Fibrous Tumors 1Soft Tissue Neoplasms 1Skin Diseases 1Sarcoma, Synovial 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Recurrent High Grade Meningioma 1Pancreatic Neoplasms 1Ovarian Diseases 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Mesothelioma 1Malignant mesenchymal tumor 1

Interventions

Ocoxin 2tariquidar 1niraparib 1Trabectedin 1Sunitinib 1Psilocybin 1Dexamethasone 1Denosumab 1Bevacizumab 1Ascorbic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Endocrine Gland Neoplasms × Trabectedin × Clear all
NCT00050414 2013-01-10

A Study of Trabectedin in Patients With Advanced Ovarian Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
147 enrolled
Gynecologic

Adnexal Diseases, Endocrine Gland Neoplasms, Genital Diseases, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡